Drug Profile
Sulcardine - HUYA Bioscience International
Alternative Names: HBI-3000; Sulcardine sulfate - HUYA Bioscience International; Sulcardine sulphate - HUYA Bioscience InternationalLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Jiangsu Furui Pharmaceuticals; Shanghai Institute of Materia Medica
- Developer HUYA Bioscience International; Jiangsu Furui Pharmaceuticals
- Class Antiarrhythmics; Benzene derivatives; Ethers; Pyrrolidines; Small molecules; Sulfonamides
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atrial fibrillation
- No development reported Arrhythmias
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Atrial-fibrillation(In volunteers) in United Kingdom (IV, Infusion)
- 18 May 2022 HUYA Bioscience completes a phase I clinical trial in Atrial fibrillation (In volunteers) in USA and Australia (IV) (NCT04650542)
- 01 Jun 2021 Phase-II clinical trials in Atrial fibrillation (In adults, In the elderly) in Australia, Bosnia-Herzegovina, Serbia, South Korea, Canada (IV) (NCT04680026)